Bacardi Shakes up Cocktails-at-Home With Launch of TAILS® COCKTAILS
30.3.2022 13:30:00 EEST | Business Wire | Press release
Bacardi, the largest privately held spirits company in the world, is raising the bar for cocktails-at-home with the launch of TAILS COCKTAILS.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005116/en/
BACARDI SHAKES UP COCKTAILS-AT-HOME WITH LAUNCH OF TAILS® COCKTAILS. (Photo: Business Wire)
This is the first time this new range of premium batched cocktails from TAILS will be available for consumers to enjoy at home. The brand was originally created for the hospitality industry, offering a hassle-free solution for serving premium quality cocktails easily, quickly and consistently.
“Over the last two years, cocktail awareness has boomed as people served up daiquiris, espresso martini cocktails and mojitos to make staying-in feel extra special,” said Evert-Jan Bos, General Manager of TAILS. “Now, as the on-trade reopens, consumers are enjoying the experience of being back in the bar and they’re ordering cocktails more than ever before.”
To tap into this thriving cocktail culture, TAILS is bringing a taste of the bar home with new-look packaging and new recipes. Made using the Bacardi portfolio of premium brands blended with top quality ingredients, the pre-batched cocktail range is perfectly positioned for the rise in entertaining at home, and an ever-growing demand for hyper-convenience. People can now enjoy the experience of shaking up a bar quality cocktail in just 30 seconds, with no planning required.
Evert-Jan adds: “This is a game-changer for the home bar. TAILS COCKTAILS offer both incredible taste and convenience, making it easier than ever for people to enjoy the same flavor and complexity of a cocktail made from scratch, without any effort or expertise. No shopping for ingredients, no measuring, no recipes - just add ice, shake and pour – how easy is that?”
There are five TAILS COCKTAILS - the ‘Rum Daiquirí’ made with BACARDÍ® rum; the ‘Whisky Sour’ with DEWAR’S® Blended Scotch whisky; the ‘Gin Gimlet’ with BOMBAY SAPPHIRE® gin; and the ‘Espresso Martini Cocktail’ and ‘Passion Fruit Martini Cocktail’, both made with 42BELOW® vodka.
Francis Debeuckelaere, Regional President, Western Europe, Australia & New Zealand, comments: “Of course you can never replace the experience of enjoying a favorite cocktail in a local bar, however we’re going one step further to offer more and more fantastic choices for consumers. With TAILS we’re delivering new experiences for the home, putting cocktails on the menu whatever the occasion. We are pioneering a whole new ‘ready-to-shake’ category.”
A QR code on every 50cl bottle links to a 30 second ‘how to’ video which explains the three simple serving steps, along with garnish suggestions, for each cocktail: 1, add ice and 125ml of the TAILS cocktail to a shaker; 2, experience that ‘bartender feeling’ by shaking until ice cold; and 3, pour into a glass.
TAILS will be available from April in supermarkets, specialist liquor stores and online across the UK & Ireland, Netherlands, Belgium, Germany, Austria, and Australia, supported by a digital-first marketing campaign focused on building awareness and driving trial of the new range.
For more information on TAILS COCKTAILS, visit www.tailscocktails.com.
Always drink responsibly.
About TAILS®
TAILS COCKTAILS is an exclusive range of premium pre-batched cocktails that bring the experience of the bar to consumers’ homes, with all the flavor and complexity of hand-made cocktails, but none of the effort. Established in 2010, TAILS was founded with a vision to make high-quality cocktails more accessible to a wider audience of cocktail lovers. Each TAILS COCKTAIL begins with the highest quality, premium spirits – BACARDI® Rum, 42BELOW® Vodka, BOMBAY SAPPHIRE® Gin and DEWAR’S® Blended Scotch whisky – blended with top quality ingredients. The TAILS brand is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda.
Visit www.tailscocktails.com.
About Bacardi
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded over 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005116/en/
Contact information
Phillippa Williams, Corporate Communications Manager, Western Europe, Australia & New Zealand, pholmes@bacardi.com
Andrew Carney, Corporate Communications Director, Western Europe, Australia & New Zealand, acarney@bacardi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
